PhosLo: Advanced Phosphate Control for Renal Health
PhosLo
| Product dosage: 667mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.40 | $48.00 (0%) | 🛒 Add to cart |
| 30 | $1.73 | $72.00 $52.00 (28%) | 🛒 Add to cart |
| 60 | $1.07 | $144.00 $64.00 (56%) | 🛒 Add to cart |
| 90 | $0.84 | $216.00 $76.00 (65%) | 🛒 Add to cart |
| 120 | $0.73 | $288.00 $88.00 (69%) | 🛒 Add to cart |
| 180 | $0.62 | $432.00 $112.00 (74%) | 🛒 Add to cart |
| 270 | $0.61 | $648.00 $164.00 (75%) | 🛒 Add to cart |
| 360 | $0.60
Best per pill | $864.00 $217.00 (75%) | 🛒 Add to cart |
Synonyms | |||
PhosLo (calcium acetate) is a prescription phosphate binder specifically formulated for the management of hyperphosphatemia in patients with end-stage renal disease. By effectively reducing serum phosphate levels, it plays a critical role in mitigating the risk of renal osteodystrophy and cardiovascular calcification. This medication is a cornerstone in nephrology care, supporting long-term patient outcomes through precise biochemical management.
Features
- Active ingredient: Calcium acetate
- Available in 667 mg tablets
- Functions as a phosphate binder in the gastrointestinal tract
- Designed for oral administration with meals
- Manufactured under strict pharmaceutical quality standards
- Prescription-only medication
Benefits
- Effectively lowers serum phosphate levels in dialysis patients
- Reduces the risk of secondary hyperparathyroidism and bone disease
- Helps prevent soft tissue and vascular calcification
- Supports overall mineral and bone disorder management in CKD
- May decrease mortality associated with hyperphosphatemia complications
- Provides predictable phosphate binding with meal consumption
Common use
PhosLo is primarily indicated for the control of hyperphosphatemia in patients with end-stage renal disease who are on dialysis. It is commonly prescribed as part of a comprehensive renal management protocol that includes dietary phosphate restriction and dialysis. The medication works by binding dietary phosphate in the digestive tract, forming insoluble calcium phosphate complexes that are excreted in feces rather than absorbed into the bloodstream.
Dosage and direction
The initial dosage is typically 2 tablets (1334 mg) with each meal, which may be adjusted gradually to achieve target serum phosphate levels. Dosage should be individualized based on serum phosphate levels, generally not exceeding 12 tablets daily. Tablets should be taken with meals or immediately following food intake to maximize phosphate binding efficiency. Tablets should be swallowed whole and not crushed or chewed.
Precautions
Regular monitoring of serum calcium and phosphate levels is essential during therapy. Patients should be cautioned about possible hypercalcemia, particularly those with conditions predisposing to calcium accumulation. Use with caution in patients with sarcoidosis or those taking digitalis preparations. Calcium acetate should not be used as a calcium supplement outside its indicated use as a phosphate binder.
Contraindications
PhosLo is contraindicated in patients with hypercalcemia. It should not be administered to patients with known hypersensitivity to calcium acetate or any component of the formulation. The medication is not recommended for patients who are not on dialysis or those with normal renal function.
Possible side effects
Common adverse reactions may include hypercalcemia, nausea, vomiting, loss of appetite, constipation, and dry mouth. Less frequently, patients may experience pruritus, headache, weakness, or dizziness. Severe hypercalcemia may manifest as confusion, delirium, stupor, or coma. Gastrointestinal symptoms often diminish with continued use or dosage adjustment.
Drug interaction
Concurrent use with calcium channel blockers may reduce their effectiveness. Absorption of tetracycline antibiotics may be decreased when administered with PhosLo. Corticosteroids may enhance calcium absorption. Quinidine levels may be increased when taken concurrently. Patients taking digitalis should be monitored closely due to potential synergistic effects on cardiac rhythm.
Missed dose
If a dose is missed, it should be taken as soon as remembered with food. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Patients should not double the dose to make up for a missed administration. Consistent dosing with meals is crucial for optimal phosphate control.
Overdose
Overdose may lead to severe hypercalcemia, manifested by nausea, vomiting, anorexia, constipation, abdominal pain, dry mouth, thirst, polyuria, and lethargy. Progressive hypercalcemia can result in confusion, delirium, stupor, coma, and cardiac arrhythmias. Treatment involves discontinuation of therapy, low-calcium diet, and supportive measures. Hemodialysis against a low-calcium bath may be necessary in severe cases.
Storage
Store at room temperature (20-25°C or 68-77°F) in a dry place protected from light and moisture. Keep the container tightly closed and out of reach of children. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers that may not provide adequate protection from moisture.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting or changing any medication regimen. Individual patient needs may vary, and proper medical supervision is essential for safe and effective use of PhosLo.
Reviews
Clinical studies demonstrate that PhosLo effectively reduces serum phosphate levels in approximately 70-80% of dialysis patients when used as directed. Nephrologists report satisfactory phosphate control with appropriate dosing adjustments. Patient satisfaction surveys indicate good tolerability when dosage is properly titrated, though gastrointestinal side effects remain a consideration for some individuals.